https://www.selleckchem.com/pr....oducts/Avasimibe(CI-
The resulting discrepancy of claims vs primary data between 0.17% and 0.77% indicates the most probable spectrum of vitiligo prevalence in Germany. It is more frequently observed in clinical exams than recorded in claims data, indicating a marked proportion of people seeking no medical help. Such nonattendance may result from the fact that many treatment options do not provide satisfying benefits to the patients. The resulting discrepancy of claims vs primary data between 0.17% and 0.77% indicates the most probable spectrum o
Like
Comment
Share
